Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity

Tessandra Stewart, Vesna Sossi, Jan O. Aasly, Zbigniew K Wszolek, Ryan J. Uitti, Kazuko Hasegawa, Teruo Yokoyama, Cyrus P. Zabetian, James B. Leverenz, Alexander Jon Stoessl, Yu Wang, Carmen Ginghina, Changqin Liu, Kevin C. Cain, Peggy Auinger, Un Jung Kang, Poul Henning Jensen, Min Shi, Jing Zhang

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

INTRODUCTION: α-Synuclein (α-syn) is a key protein in Parkinson's disease (PD), and one of its phosphorylated forms, pS129, is higher in PD patients than healthy controls. However, few studies have examined its levels in longitudinally collected cerebrospinal fluid (CSF) or in preclinical cases. In this study, CSF and clinical data were contributed by >300 subjects from three cohorts (the longitudinal DATATOP cohort, a large cross-sectional cohort, and a cohort of LRRK2 mutation carriers).

RESULTS: Consistent with our previous observation that CSF pS129 positively correlated with Unified Parkinson's Disease Rating Scale (UPDRS) scores, CSF pS129 in the DATATOP cohort increased over approximately two years of disease progression (mean change 5.60 pg/ml, p = 0.050). Intriguingly, in the DATATOP cohort, pS129 negatively correlated with UPDRS scores at the baseline (R = -0.244, p = 0.017), but not final point, suggesting that this association may depend on disease stage. Reanalysis of our previous cohort with stratification by PD stage, and addition of a cohort of LRRK2 mutation carriers with very early/preclinical PD, supported the idea that the relationship between CSF pS129 and disease severity over a wider range of PD stages might be represented with a U-shaped curve, in which lower pS129 levels correlated with worse clinical condition at early stages, but better condition at later stages.

CONCLUSION: The observation of a negative-to-positive transition of correlation of pS129 to disease severity as PD progresses could have profound impact on how pS129 is used as a biomarker clinically as well as in modeling PD experimentally.

Original languageEnglish (US)
Pages (from-to)7
Number of pages1
JournalActa neuropathologica communications
Volume3
DOIs
StatePublished - Jan 31 2015

Fingerprint

Synucleins
Parkinson Disease
Cerebrospinal Fluid
Mutation
Disease Progression
Biomarkers
Observation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Phosphorylated α-synuclein in Parkinson's disease : correlation depends on disease severity. / Stewart, Tessandra; Sossi, Vesna; Aasly, Jan O.; Wszolek, Zbigniew K; Uitti, Ryan J.; Hasegawa, Kazuko; Yokoyama, Teruo; Zabetian, Cyrus P.; Leverenz, James B.; Stoessl, Alexander Jon; Wang, Yu; Ginghina, Carmen; Liu, Changqin; Cain, Kevin C.; Auinger, Peggy; Kang, Un Jung; Jensen, Poul Henning; Shi, Min; Zhang, Jing.

In: Acta neuropathologica communications, Vol. 3, 31.01.2015, p. 7.

Research output: Contribution to journalArticle

Stewart, T, Sossi, V, Aasly, JO, Wszolek, ZK, Uitti, RJ, Hasegawa, K, Yokoyama, T, Zabetian, CP, Leverenz, JB, Stoessl, AJ, Wang, Y, Ginghina, C, Liu, C, Cain, KC, Auinger, P, Kang, UJ, Jensen, PH, Shi, M & Zhang, J 2015, 'Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity', Acta neuropathologica communications, vol. 3, pp. 7. https://doi.org/10.1186/s40478-015-0185-3
Stewart, Tessandra ; Sossi, Vesna ; Aasly, Jan O. ; Wszolek, Zbigniew K ; Uitti, Ryan J. ; Hasegawa, Kazuko ; Yokoyama, Teruo ; Zabetian, Cyrus P. ; Leverenz, James B. ; Stoessl, Alexander Jon ; Wang, Yu ; Ginghina, Carmen ; Liu, Changqin ; Cain, Kevin C. ; Auinger, Peggy ; Kang, Un Jung ; Jensen, Poul Henning ; Shi, Min ; Zhang, Jing. / Phosphorylated α-synuclein in Parkinson's disease : correlation depends on disease severity. In: Acta neuropathologica communications. 2015 ; Vol. 3. pp. 7.
@article{360c1ad706b44ebf9bfa7efa69421665,
title = "Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity",
abstract = "INTRODUCTION: α-Synuclein (α-syn) is a key protein in Parkinson's disease (PD), and one of its phosphorylated forms, pS129, is higher in PD patients than healthy controls. However, few studies have examined its levels in longitudinally collected cerebrospinal fluid (CSF) or in preclinical cases. In this study, CSF and clinical data were contributed by >300 subjects from three cohorts (the longitudinal DATATOP cohort, a large cross-sectional cohort, and a cohort of LRRK2 mutation carriers).RESULTS: Consistent with our previous observation that CSF pS129 positively correlated with Unified Parkinson's Disease Rating Scale (UPDRS) scores, CSF pS129 in the DATATOP cohort increased over approximately two years of disease progression (mean change 5.60 pg/ml, p = 0.050). Intriguingly, in the DATATOP cohort, pS129 negatively correlated with UPDRS scores at the baseline (R = -0.244, p = 0.017), but not final point, suggesting that this association may depend on disease stage. Reanalysis of our previous cohort with stratification by PD stage, and addition of a cohort of LRRK2 mutation carriers with very early/preclinical PD, supported the idea that the relationship between CSF pS129 and disease severity over a wider range of PD stages might be represented with a U-shaped curve, in which lower pS129 levels correlated with worse clinical condition at early stages, but better condition at later stages.CONCLUSION: The observation of a negative-to-positive transition of correlation of pS129 to disease severity as PD progresses could have profound impact on how pS129 is used as a biomarker clinically as well as in modeling PD experimentally.",
author = "Tessandra Stewart and Vesna Sossi and Aasly, {Jan O.} and Wszolek, {Zbigniew K} and Uitti, {Ryan J.} and Kazuko Hasegawa and Teruo Yokoyama and Zabetian, {Cyrus P.} and Leverenz, {James B.} and Stoessl, {Alexander Jon} and Yu Wang and Carmen Ginghina and Changqin Liu and Cain, {Kevin C.} and Peggy Auinger and Kang, {Un Jung} and Jensen, {Poul Henning} and Min Shi and Jing Zhang",
year = "2015",
month = "1",
day = "31",
doi = "10.1186/s40478-015-0185-3",
language = "English (US)",
volume = "3",
pages = "7",
journal = "Acta neuropathologica communications",
issn = "2051-5960",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Phosphorylated α-synuclein in Parkinson's disease

T2 - correlation depends on disease severity

AU - Stewart, Tessandra

AU - Sossi, Vesna

AU - Aasly, Jan O.

AU - Wszolek, Zbigniew K

AU - Uitti, Ryan J.

AU - Hasegawa, Kazuko

AU - Yokoyama, Teruo

AU - Zabetian, Cyrus P.

AU - Leverenz, James B.

AU - Stoessl, Alexander Jon

AU - Wang, Yu

AU - Ginghina, Carmen

AU - Liu, Changqin

AU - Cain, Kevin C.

AU - Auinger, Peggy

AU - Kang, Un Jung

AU - Jensen, Poul Henning

AU - Shi, Min

AU - Zhang, Jing

PY - 2015/1/31

Y1 - 2015/1/31

N2 - INTRODUCTION: α-Synuclein (α-syn) is a key protein in Parkinson's disease (PD), and one of its phosphorylated forms, pS129, is higher in PD patients than healthy controls. However, few studies have examined its levels in longitudinally collected cerebrospinal fluid (CSF) or in preclinical cases. In this study, CSF and clinical data were contributed by >300 subjects from three cohorts (the longitudinal DATATOP cohort, a large cross-sectional cohort, and a cohort of LRRK2 mutation carriers).RESULTS: Consistent with our previous observation that CSF pS129 positively correlated with Unified Parkinson's Disease Rating Scale (UPDRS) scores, CSF pS129 in the DATATOP cohort increased over approximately two years of disease progression (mean change 5.60 pg/ml, p = 0.050). Intriguingly, in the DATATOP cohort, pS129 negatively correlated with UPDRS scores at the baseline (R = -0.244, p = 0.017), but not final point, suggesting that this association may depend on disease stage. Reanalysis of our previous cohort with stratification by PD stage, and addition of a cohort of LRRK2 mutation carriers with very early/preclinical PD, supported the idea that the relationship between CSF pS129 and disease severity over a wider range of PD stages might be represented with a U-shaped curve, in which lower pS129 levels correlated with worse clinical condition at early stages, but better condition at later stages.CONCLUSION: The observation of a negative-to-positive transition of correlation of pS129 to disease severity as PD progresses could have profound impact on how pS129 is used as a biomarker clinically as well as in modeling PD experimentally.

AB - INTRODUCTION: α-Synuclein (α-syn) is a key protein in Parkinson's disease (PD), and one of its phosphorylated forms, pS129, is higher in PD patients than healthy controls. However, few studies have examined its levels in longitudinally collected cerebrospinal fluid (CSF) or in preclinical cases. In this study, CSF and clinical data were contributed by >300 subjects from three cohorts (the longitudinal DATATOP cohort, a large cross-sectional cohort, and a cohort of LRRK2 mutation carriers).RESULTS: Consistent with our previous observation that CSF pS129 positively correlated with Unified Parkinson's Disease Rating Scale (UPDRS) scores, CSF pS129 in the DATATOP cohort increased over approximately two years of disease progression (mean change 5.60 pg/ml, p = 0.050). Intriguingly, in the DATATOP cohort, pS129 negatively correlated with UPDRS scores at the baseline (R = -0.244, p = 0.017), but not final point, suggesting that this association may depend on disease stage. Reanalysis of our previous cohort with stratification by PD stage, and addition of a cohort of LRRK2 mutation carriers with very early/preclinical PD, supported the idea that the relationship between CSF pS129 and disease severity over a wider range of PD stages might be represented with a U-shaped curve, in which lower pS129 levels correlated with worse clinical condition at early stages, but better condition at later stages.CONCLUSION: The observation of a negative-to-positive transition of correlation of pS129 to disease severity as PD progresses could have profound impact on how pS129 is used as a biomarker clinically as well as in modeling PD experimentally.

UR - http://www.scopus.com/inward/record.url?scp=85017330543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017330543&partnerID=8YFLogxK

U2 - 10.1186/s40478-015-0185-3

DO - 10.1186/s40478-015-0185-3

M3 - Article

C2 - 25637461

AN - SCOPUS:85017330543

VL - 3

SP - 7

JO - Acta neuropathologica communications

JF - Acta neuropathologica communications

SN - 2051-5960

ER -